Page 23 - Journal of Structural Heart Disease Volume 5, Issue 2

Original Scientific Article 36
Figure 5. Aortic root angiogram confirming prosthesis positioning predeployment. Siemens Cios Alpha, PAS (Panel A). Philips Allura Xper FD20, MAS (Panel B). Inset, corresponding fluoroscopic camera.
tween subgroups and the composite safety outcome of any adverse event at 30 days.
In conclusion, our study demonstrates that PAS is a safe and effective imaging modality for TAVR pro- cedures with less total radiation exposure than MAS. Future prospective studies with larger sample sizes are needed to clarify this finding.
Acknowledgement
The authors thank Dr. Afzal ur Rehman, MD, PhD, for his insightful review and critique of the manu- script; Dr. Gary James, PhD, for his assistance with the
References
1. Leon MB, Smith CR, Mack M, Miller DC, Mo- ses JW, Svensson LG, et al. Transcatheter aortic-valve implantation for aortic steno- sis in patients who cannot undergo sur- gery. N Engl J Med. 2010;363:1597-1607. DOI: 10.1097/01.sa.0000396024.48515.95
2. Makkar RR, Fontana GP, Jilaihawi H, Kapa- dia S, Pichard AD, Douglas PS, et al. Tran- scatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med. 2012;366:1696-1704. DOI: 10.1056/ NEJMoa1202277
statistical analysis; Dr. Mouhamed Sabouni, MD, for his review and editing of the manuscript; and Mary Cina, RN, for providing helpful information during data collection.
Conflict of Interest
The authors have no conflict of interest relevant to this publication.
Comment on this Article or Ask a Question
3.
4.
Tamburino C, Capodanno D, Ramondo A, Petronio AS, Ettori F, Santoro G, et al. In- cidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. Circulation. 2011;123:299-
308. DOI: 10.1161/CIRCULATIONA- HA.110.946533 6. Smith CR, Leon MB, Mack MJ, Miller C, Moses JW, Svensson LG, et al. Transcath-
eter versus surgical aortic-valve replace- ment in high-risk patients. N Engl J Med.
2011;364:2187-2198. DOI: 10.12968/bj- ca.2011.6.11.564a
Webb JG. Percutaneous aortic valve re- placement will become a common treat- ment for aortic valve disease. JACC Cardio- vasc Interv. 2008;1:122-126. DOI: 10.1016/j. jcin.2007.11.010
Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739- 91. DOI: 10.1093/eurheartj/ehx391
5.
Journal of Structural Heart Disease, April 2019
Volume 5, Issue 2:25-37